【24h】

Rotavirus vaccines: a story of success

机译:轮状病毒疫苗:成功的故事

获取原文
获取原文并翻译 | 示例
           

摘要

By January 2015, rotavirus vaccination had been implemented in national vaccination programmes in 75 countries worldwide. Two live oral rotavirus vaccines are internationally available: human, monovalent vaccine and human bovine pentavalent reassortant vaccine. Since January 2014, another live, oral human bovine monovalent vaccine has been available in India. After implementation of rotavirus vaccines in childhood immunization programmes, there has been an over 90% reduction of rotavirus hospitalizations in industrialized and resource-deprived countries. Additionally, in Latin America, significant reduction of rotavirus-associated deaths has been recorded. Still, numerous countries do not recommend rotavirus mass vaccination because of assumed lack of cost-effectiveness and potential risk of intussusception, which is estimated at I per 50 000-70 000 doses of rotavirus vaccines. Cost-effectiveness of vaccination is affected in some countries by high price. Inclusion of herd protection and indirect costs in calculations for cost-effectiveness results in clear benefit costs saved by health systems due to reduced rotavirus gastroenteritis hospitalizations far exceed the costs for implementation of rotavirus vaccination. There have been objections that high rotavirus vaccination coverage could put selective pressure on certain rotavirus strains against which protection after vaccination is less distinct. However, data now strongly suggest that even if there might be a relative increase of some specific genotypes after the use of rotavirus vaccines, this is not an absolute increase in incidence from certain genotypes and does not affect the overall effectiveness of rotavirus mass vaccination, which resulted in a major decrease of severe cases of rotavirus gastroenteritis in both industrialized and resource deprived countries. Clinical Microbiology and Infection (C) 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
机译:到2015年1月,轮状病毒疫苗已经在全球75个国家的国家疫苗接种计划中实施。目前有两种口服口服轮状病毒活疫苗:人单价疫苗和人牛五价重配疫苗。自2014年1月起,印度已推出另一种口服人类牛单价活疫苗。在儿童免疫计划中实施轮状病毒疫苗后,在工业化和资源匮乏的国家中,轮状病毒住院治疗减少了90%以上。另外,在拉丁美洲,已经记录到轮状病毒相关死亡的显着减少。但是,由于假定缺乏成本效益和肠套叠的潜在风险,许多国家不建议轮状病毒疫苗接种,据估计,每5万至7万剂轮状病毒疫苗中就有1例发生肠套叠。在某些国家,疫苗的成本效益受到高价的影响。在成本效益计算中包括畜群保护和间接成本,由于轮状病毒胃肠炎住院减少,卫生系统节省了明显的收益成本,远远超过了实施轮状病毒疫苗接种的成本。有反对意见认为,高轮状病毒疫苗接种覆盖率可能会对某些轮状病毒株施加选择性压力,而对这些轮状病毒株接种后的保护作用不太明显。但是,现在的数据有力地表明,即使使用轮状病毒疫苗后某些特定基因型可能相对增加,但这也不是某些基因型发生率的绝对增加,也不影响轮状病毒大规模疫苗接种的总体效果。在工业化国家和资源匮乏的国家中,轮状病毒胃肠炎的严重病例大大减少。临床微生物学和感染(C)2015年欧洲临床微生物学和传染病学会。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号